Capsugel has announced that it will acquire CDMO Xcelience and micronization services provider Powdersize in order to “enhance Capsugel’s position as a leading provider of innovative dosage forms and solutions to healthcare customers around the world.” Both companies will become part of Capsugel’s Dosage Form Solutions business unit. Terms of the deal were undisclosed.
In 2011, Xcelience announced that it was adding micro-dosing capacity for DPI clinical trial supply manufacturing. Capsugel has already introduced DPI clinical trial supply manufacturing services through its subsidiary Bend Research, which it acquired in 2013.
Capsugel President and CEO Guido Driesen commented, “The additions of Xcelience and Powdersize accelerate Capsugel’s strategy to expand our service offerings through continued investments in new capabilities and technologies. The expertise and high levels of service that we gain in this transaction will make us an even stronger, more-differentiated partner as we collaborate with pharmaceutical companies to bring better medicines to patients.”
Read the Capsugel press release.
